Sterling Capital Management’s Climb Bio CLYM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.5K Buy
918
+466
+103% +$6.49K ﹤0.01% 2505
2026
Q2
$5.89K Buy
+452
New +$4.67K ﹤0.01% 2523
2025
Q2
– Sell
-479
Closed -$584 – 3430
2025
Q1
$584 Sell
479
-462
-49% -$749 ﹤0.01% 2939
2024
Q4
$1.69K Buy
941
+829
+740% +$3K ﹤0.01% 2823
2024
Q3
$570 Buy
+112
New +$792 ﹤0.01% 2804

Other funds holding CLYM

Sterling Capital Management's CLYM Position: Q3 2026 in Review

Sterling Capital Management increased its Climb Bio (CLYM) stake by 103% in Q3 2026, buying an estimated $6.49K and bringing the position to 918 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2505.

Sterling Capital Management first reported a position in CLYM in Q3 2024 and has held it in 5 quarters since. 128 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.

  • Sterling Capital Management held 918 shares of Climb Bio worth $10.5K as of Q3 2026.
  • Sterling Capital Management bought 466 Climb Bio shares in Q3 2026, an estimated $6.49K.
  • Climb Bio made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2505 holding.
  • Sterling Capital Management first reported a position in Climb Bio in Q3 2024 and has held it in 5 quarters since.
  • 128 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.